Perampanel as an Adjunctive Treatment in 3 Patients with Glioblastoma Multiforme (GBM) with Refractory Seizures (P2.057)
Patricio S Espinosaa b, R. Perez Soteloc, Armand Golchind, Rima Bakhdad, Jose Valdese f, Patricio H Espinosa del Pozog h
- aMarcus Neuroscience Institute/Florida Atlantic University Boca Raton FL United States
- bNeurology Department Florida Atlantic University Boca Raton FL United States
- cNeurology Department Marcus Neuroscience Institute Boca Raton FL United States
- dInternal Medicine Florida Atlantic University Boca Raton FL United States
- eNeurology &
- fNeuropsychiatry Marcus Neuroscience Institute Boca Raton FL United States
- gCumbaya Quito Ecuador
- hUnidad de Neurociencias Universidad Central del Ecuador Quito Ecuador
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
OBJECTIVE: To assess the efficacy of perampanel in patients with GBM with refractory epilepsy. BACKGROUND: Malignant gliomas are known to release glutamate which is involved in tumor expansion and epileptogenesis. By blocking α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors stimulated by glutamate, seizure control may be achieved. Perampanel, a noncompetitive AMPA glutamate receptor antagonist, has been shown to be an effective adjunctive treatment in patients with epilepsy. DESIGN/METHODS: We describe 3 patients with GBM and refractory epilepsy that achieved seizure control with the addition of perampanel to their current regimen. RESULTS: Case1. Patient is a 61 year old woman with recurrent seizures on levetiracetam and oxcarbazepine. Perampanel was added and the patient has been seizure free for over 3 months. Case 2. Patient is a 64 year old man with GBM and partial status epilepticus on valproic acid, levetiracetam and lacosamide. Perampanel was added and the focal seizures decreased significantly. The patient passed away after 5 weeks due to complications of GBM. Case 3. Patient 68 year old man with GBM status post 2 surgeries and epilepsia partialis continua on levetiracetam, valproic acid and carbamazepine. Perampanel was added and he has remained seizure free for over 5 weeks. CONCLUSIONS: Perampanel is efficacious and well tolerated as an adjunctive anti-epileptic drug in our patients with GBM and refractory seizures. Disclosure: Dr. Espinosa has nothing to disclose. Dr. Sotelo has nothing to disclose. Dr. Golchin has nothing to disclose. Dr. Bakhda has nothing to disclose. Dr. Valdes has nothing to disclose. Dr. Espinosa Del Pozo has nothing to disclose.
TL;DRPerampanel is efficacious and well tolerated as an adjunctive anti-epileptic drug in patients with GBM and refractory seizures. (Semantic Scholar)